Biotech Listings Under Chapter 18A: How Pre-Revenue Companies Can Satisfy the HKEX

Hong Kong’s Chapter 18A listing regime, introduced in April 2018, has fundamentally altered the capital-raising calculus for pre-revenue biotechnology companies. As of Q1 2025, the HKEX has admitted 67 biotech issuers under Chapter 18A, raising a combined HKD 127.8 billion in primary proceeds, according to exchange data. This pathway remains the most viable option for clinical-stage drug developers and medical device makers seeking public market access without a proven revenue stream. However, the regulatory landscape is not static: the SFC and HKEX have tightened disclosure requirements for pre-revenue biotech listings, particularly around pipeline valuation methodologies and risk factor granularity, following a series of post-IPO performance disappointments. For company secretaries, CFOs, and sponsor counsel advising pre-revenue biotech issuers, understanding the precise mechanics of Chapter 18A eligibility—from core product requirements to the minimum market capitalisation threshold of HKD 1.5 billion—is no longer optional. This article dissects the operational and regulatory prerequisites for a successful Chapter 18A listing, drawing on the HKEX Listing Rules, the SFC’s Code of Conduct, and recent Listing Decisions to provide a compliance roadmap for 2025-2026.

The Core Eligibility Thresholds Under Chapter 18A

Chapter 18A of the HKEX Main Board Listing Rules carves out a specific exemption for biotechnology companies that cannot satisfy the standard profit or revenue tests. The regime applies to companies primarily engaged in the research and development, application, or commercialisation of “biotech products,” defined broadly to include pharmaceuticals, biologics, and medical devices. Critical to any application is the demonstration that the issuer meets the “core product” requirement, which mandates that at least one product has progressed beyond the concept stage and has been approved by a competent authority for clinical trials in a recognised jurisdiction.

The HKD 1.5 Billion Market Capitalisation Floor

A pre-revenue biotech applicant must have a minimum market capitalisation at listing of HKD 1.5 billion. This is not a soft target; it is a hard floor codified in Rule 18A.03(2). The HKEX requires the sponsor to provide a detailed valuation analysis, typically using a risk-adjusted net present value (rNPV) model or a comparable company analysis. The Listing Division has, in recent guidance (HKEX Listing Decision LD127-2023), flagged that valuations relying solely on peer multiples without a robust pipeline-specific discount rate are unlikely to be accepted. The sponsor must also demonstrate that the market capitalisation is sustainable post-listing—meaning the issuer’s cash runway, clinical milestones, and patent cliff dates must support the valuation narrative for at least 12 months post-IPO.

The Core Product Requirement: Phase II or Beyond

To satisfy the core product requirement under Rule 18A.03(3), the company must have at least one product that has successfully completed Phase I clinical trials and is either in Phase II or has received regulatory approval to commence Phase II trials in a recognised jurisdiction. The HKEX maintains a non-exhaustive list of acceptable regulators: the US FDA, the European Medicines Agency (EMA), China’s NMPA, and Japan’s PMDA. For medical device companies, the equivalent hurdle is a CE marking or FDA 510(k) clearance for a device that has demonstrated safety and efficacy in a clinical study. The HKEX has also accepted applications where the core product has received a “breakthrough therapy designation” from the FDA, even if Phase II has not formally commenced, provided the sponsor can justify the accelerated pathway.

The Disclosure and Sponsor Obligations

The SFC’s Code of Conduct for Corporate Finance Advisors imposes heightened due diligence standards on sponsors for Chapter 18A listings. The sponsor must verify the scientific basis of the issuer’s claims, including the integrity of clinical trial data, the qualifications of the principal investigators, and the intellectual property chain of title. This is not a box-ticking exercise; the SFC has publicly reprimanded two sponsors in 2024 for inadequate due diligence on preclinical data in biotech prospectuses.

Risk Factor Disclosure: Beyond Boilerplate

The HKEX Listing Decision LD131-2024 explicitly requires that risk factors in a Chapter 18A prospectus be “product-specific and quantified where possible.” Generic statements such as “clinical trials may fail” are insufficient. The issuer must disclose the statistical probability of success for its lead candidate based on historical phase-transition rates for its therapeutic area, citing published data from sources such as the Biotechnology Innovation Organization (BIO) or the FDA. For example, if the core product is a Phase II oncology asset, the prospectus should state that the historical Phase II-to-Phase III success rate for oncology is 24.6% (BIO, 2023), and explain how this informs the valuation. The sponsor must also detail the issuer’s cash burn rate, expressed as HKD per month, and the expected cash runway to the next clinical data readout.

The Independent Expert Report

Rule 18A.06 requires the issuer to appoint an independent expert—typically a qualified medical doctor or PhD with relevant therapeutic area expertise—to prepare a report on the core product’s scientific rationale, clinical development plan, and regulatory pathway. The expert cannot be a director, employee, or shareholder of the issuer. The report must be included in the prospectus and must explicitly address any material discrepancies between the issuer’s internal projections and the expert’s independent assessment. The HKEX has rejected two applications in 2024 where the expert report was deemed insufficiently detailed on the mechanism of action or failed to address potential safety signals from non-clinical studies.

Post-Listing Compliance and the Path to Profitability

Once listed, Chapter 18A issuers face ongoing obligations that differ from standard Main Board companies. The most significant is the requirement to maintain a “sufficient level of operations” to justify continued listing under Rule 13.24. For a pre-revenue biotech, this means the company must demonstrate active clinical development, including at least one ongoing clinical trial for its core product, and sufficient cash to fund operations for the next 12 months. Failure to do so can trigger a suspension under the HKEX’s delisting framework.

The “Biotech Status” and the Viability of a Transfer to the Main Board

A Chapter 18A issuer remains classified as a “biotech company” under the Listing Rules until it meets the standard revenue and profit tests. Rule 18A.10 permits a transfer to the Main Board under Chapter 9A (the standard listing regime) once the company satisfies the profit test (HKD 50 million in the most recent year and HKD 100 million in the two preceding years) or the revenue test (HKD 500 million in the most recent year with a market cap of HKD 4 billion). As of 2025, only 11 of the 67 Chapter 18A issuers have successfully transferred to the Main Board, with an average time from listing to transfer of 4.2 years. The remainder continue to trade under the Chapter 18A designation, subject to the more restrictive disclosure and compliance requirements.

The Role of Post-IPO Convertible Notes and At-the-Market Offerings

Given the capital-intensive nature of biotech R&D, many Chapter 18A issuers rely on post-IPO financing instruments to bridge the gap to profitability. The HKEX has issued specific guidance (HKEX Guidance Letter GL117-2023) on the disclosure requirements for convertible notes issued by biotech companies. The issuer must disclose the conversion price, the dilution impact on existing shareholders, and the specific use of proceeds for clinical trials. At-the-market (ATM) offerings, which allow issuers to sell shares directly into the market at prevailing prices, have become increasingly common, with 14 Chapter 18A companies raising a combined HKD 18.2 billion via ATM facilities in 2024. The sponsor must ensure that any ATM programme is structured to comply with the HKEX’s placement rules under Chapter 13.26, including the requirement that the issue price not be at a discount of more than 20% to the prevailing market price.

Cross-Border Structures and Jurisdictional Considerations

The majority of Chapter 18A issuers are incorporated in the Cayman Islands or Bermuda, with their primary operations in the PRC. This structure requires careful navigation of PRC regulatory requirements, particularly the China Securities Regulatory Commission’s (CSRC) filing regime for overseas listings, which came into full effect on March 31, 2023. The CSRC requires all PRC-incorporated or PRC-controlled companies seeking a Hong Kong listing to file a “Record Filing” with the CSRC within three business days of the HKEX’s acceptance of the listing application (CSRC Rules on Overseas Securities Offering and Listing, 2023). Failure to do so can result in a suspension of the listing process.

The VIE Structure and PRC Data Security

For biotech companies that operate through variable interest entities (VIEs) to comply with PRC foreign ownership restrictions in the healthcare sector, the HKEX has imposed additional disclosure requirements under Guidance Letter GL94-2022. The issuer must disclose the contractual arrangements in the VIE structure, the risks of PRC regulatory changes, and the specific data security measures in place to comply with the PRC Personal Information Protection Law (PIPL) and the Data Security Law. The SFC has, in a 2024 circular, reminded sponsors to verify that the VIE structure does not contravene PRC regulations on human genetic resources, which are governed by the PRC Human Genetic Resources Management Regulations (2019). Any clinical trial data generated in the PRC and used to support a Chapter 18A application must comply with these regulations, including the requirement to obtain informed consent from all trial participants for the use of their genetic data in an overseas listing.

The Use of BVI Holding Companies and Tax Implications

Many Chapter 18A issuers use a BVI holding company as the top-level entity, with a Hong Kong operating subsidiary that holds the PRC business. This structure offers tax advantages under the PRC-Hong Kong Double Taxation Arrangement, which provides for a reduced withholding tax rate of 5% on dividends paid from the PRC subsidiary to the Hong Kong company, provided the Hong Kong company is the “beneficial owner” of the dividends. The Inland Revenue Department (IRD) of Hong Kong has issued strict guidelines on what constitutes “beneficial ownership,” requiring the Hong Kong company to have substantive business operations, including a physical office, employees, and the ability to direct the use of the funds. A shell Hong Kong company with no substance will be denied the reduced rate, resulting in a 10% withholding tax on dividends repatriated from the PRC.

Actionable Takeaways for Issuers and Their Advisors

1. Prepare a sponsor-led valuation report that uses a risk-adjusted net present value model with a therapeutic-area-specific discount rate, and ensure the valuation is supported by a 12-month post-IPO cash runway analysis, as required by HKEX Listing Decision LD127-2023.

2. Draft the risk factor section of the prospectus with product-specific, quantified success probabilities sourced from published industry data (e.g., BIO phase-transition rates), as mandated by HKEX Listing Decision LD131-2024.

3. Engage an independent expert with demonstrable expertise in the issuer’s therapeutic area at least six months before the planned A1 filing, to allow time for a thorough scientific review and the preparation of a compliant expert report under Rule 18A.06.

4. For PRC-based issuers, complete the CSRC Record Filing within three business days of the HKEX’s acceptance of the listing application, and ensure all clinical trial data complies with the PRC Human Genetic Resources Management Regulations.

5. Structure any post-IPO convertible note or at-the-market offering to comply with HKEX Guidance Letter GL117-2023 and Chapter 13.26, including full disclosure of conversion mechanics, dilution impact, and use of proceeds for specific clinical milestones.